Physician profile
Amanda Lequire
NPI 1104287887
$4,598.02
in general payments reported to CMS, 2019-2025
42 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $487 · 2021: $958 · 2022: $1,046 · 2023: $962 · 2024: $1,145.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,107.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,107.32 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $786.06 | 2021-2024 | |
| Astrazeneca Pharmaceuticals LP | $584.11 | 2020-2024 | Breztri, Farxiga, Airsupra |
| Novo Nordisk INC | $573.47 | 2021-2024 | Rybelsus, Ozempic, Wegovy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $279.92 | 2020-2024 | Jardiance |
| Lilly USA, LLC | $263.94 | 2021-2024 | Mounjaro, Zepbound, Emgality |
| Corium, LLC | $212.36 | 2022-2024 | Azstarys |
| Pfizer INC. | $200.10 | 2023-2024 | |
| Takeda Pharmaceuticals U.S.A., INC. | $173.77 | 2020-2024 | Trintellix |
| Abbott Laboratories | $150.85 | 2021-2024 | Proclaim, Freestyle Libre 3 |
| Amgen INC. | $139.66 | 2021-2024 | Otezla, Repatha, Prolia |
| Biohaven Pharmaceuticals, INC. | $135.12 | 2020-2021 | |
| Neos Therapeutics, LP | $98.01 | 2021-2023 | Adzenys Xr-Odt |
| Otsuka America Pharmaceutical, INC. | $90.00 | 2022-2024 | Rexulti |
| Glaxosmithkline, LLC. | $86.98 | 2022-2024 | Trelegy Ellipta |
| Dexcom, INC. | $77.54 | 2024 | Dexcom G6 Transmitter |
Show all 42 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amanda Lequire listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.